Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.
BACKGROUND Cohort 1 of the phase III THOR trial met the primary endpoint of significantly longer overall survival (OS) with erdafitinib versus chemotherapy in patients with metastatic urothelial carcinoma (mUC) and select FGFR3/2 alterations who have progressed after prior anti-PD-(L)1 treatment. We present efficacy an...